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Abstract: Multidisciplinary care in is widely recommended as best practice for lung cancer in many 
countries and jurisdictions. A number of studies suggest multidisciplinary care benefits patient outcomes, 
with analyses based on a range of data sources including national, state and local registries as well as 
multidisciplinary team meeting (MDT)-based data collections, often focused on different questions 
depending on data sources. MDT data collection and linkage are not standardized and not routine although 
data collection and feedback are specifically recommended by at least one statutory body. We performed a 
scoping review of current evidence for lung cancer MDT data collection and analysis, to identify discrete 
strategies through illustrative examples and to make recommendations for future approaches. Thirteen 
studies were identified that presented lung cancer MDT-related clinical outcomes, three included MDTs 
from multiple tumour streams while 10 studies focussed on lung cancer MDT meetings. Eleven studies 
measured the effect of MDT discussion on clinical outcomes of which eight were positive. Data sources 
included MDT records (3 studies), medical or hospital records (3 studies), institutional registries (5 studies) 
and state or national administrative datasets (6 studies), with some overlap. Examples of studies based on 
different data sources (local MDT, institutional registry, national registry) exemplified the different types 
of clinical research questions appropriate for each data source. While MDT data collection is not well-
defined, the importance of clinical audit and data feedback and the potential for real-time analysis to improve 
outcomes deserve further investigation. Optimized datasets and linkage strategies are likely to maximize 
benefits for patients. 
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Introduction
Lung cancer multidisciplinary team (MDT) care (referring 
to multidisciplinary team meetings or tumour boards) is 
rapidly emerging as best practice cancer care, increasingly 
implemented across Australia, the United Kingdom, Europe 
and the United States. Presentation of cancer cases at MDT 
meetings is recommended by a number of professional 
bodies and international guidelines (1-5). Such meetings 
can require significant resources including attendance 
by specialist clinicians and allied health personnel, 
technological equipment, software and administrative 
support (6). A growing literature demonstrates potential 
benefits for lung cancer with MDT care associated with 
decreased premature mortality (7-11), treatment receipt 
and planning (8,12,13). Two review studies have highlighted 
changes and improvements in management processes as well 
as clinical outcomes for people with lung cancer through 
MDT care (14,15). The findings are based on disparate 
studies with data sources that include cancer registries and 
administrative datasets. Findings are often published some 
years after initial data collection, accounting for delays 
(appropriate for population-based registries) imposed by 
data quality requirements and access. Clinical data are 
not always routinely collected by MDTs, nor do they use 
standardised items, although many groups have published 
from their own datasets, which are often linked to local 
registries. A number have developed quality indicators to 
reflect quality of care, in particular for clinicians and health 
care providers (16-18). This manuscript reviews current 
knowledge of cancer MDT data collection and analysis with 
a focus on lung cancer, presents illustrative examples and 
recommends future directions. 
Published studies provide constructive insights into 
the potential advantages and limitations of current MDT-
based data collection. A number of teams have evaluated 
the impact of MDT practice on clinical outcomes, 
demonstrating associations between MDT care and 
treatment receipt (12), changes in treatment plans (13), 
adherence to international recommendations (19), accurate 
staging (15) and improved survival (7-11). A scoping review 
approach was chosen in order to document the evidence 
for MDT-based data collection and impact on outcomes 
and provide an overview of literature focus, according to 
previously published indications (20). Scoping reviews, as 
opposed to systematic reviews, allow mapping of literature, 
may be more inclusive and aim to determine the extent of 
evidence rather than synthesize existing evidence to answer 
specific questions (21). We have use the PRISMA-ScR 
checklist for scoping reviews to guide our approach (22).
Many health care settings typically collect clinical 
data into a range of repositories (23). These can include 
mandatory data collection, such as births and deaths, 
immunisation records and notifiable disease as well as 
curated information such as disease specific registries. 
Cancer data, including clinical lung cancer data, feed into 
jurisdictional registries in Australia and other similar health 
care settings with complex linkages and restricted access, 
appropriate for maintenance of privacy and data quality. 
However, many of these data collections are limited in their 
relevance to the busy, day-to-day practice of a working 
MDT. Questions about clinical outcomes such as timeliness 
of diagnosis and treatment, details of treatment and even 
survival for a cohort of patients cannot be quickly answered 
from these clinical registries. Delays imposed by perfectly 
reasonable access restrictions including human research 
ethics clearance and gaps in datasets (such as minimal 
treatment details in most state cancer registries) and their 
retrospective nature limit the usefulness of registry datasets 
for routine individual patient care. There is potential for 
individual MDTs to collect their own data to better answer 
questions about local treatment and outcomes although 
detailed recommendations for such MDT datasets have 
not yet been established. Questions remain about what 
information should be collected by MDTs, how to collect 
data from source systems, how to avoid duplication, how to 
best integrate into the datasets around MDT meetings such 
as local cancer registries, whether datasets should extend 
beyond single institutions and future unifying strategies at 
national levels. 
In Australia there are differences between states and 
territories. Queensland has the most advanced MDT data 
integration system through Queensland Oncology Online 
(QOOL) (24), a government-funded program that draws 
upon data feeds from all state MDTs, with analyses and 
extracts available to registered members through an online 
dashboard. This system is being tested in other states but 
is not yet established nationwide. Although many MDTs 
do extract and review data, regular audit practices are not 
routine and the ease which with teams extract and analyse 
data varies between them. Data presentation also varies; 
some teams have published analyses of local data, some 
present regular audits and some do not engage in data 
analyses at all. Questions also remain about the utility of 
local, MDT-based data collection and analysis, whether it 
changes practice, helps with implementation of change and 
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most importantly, whether it improves clinical outcomes. 
Aim
To review current knowledge of lung cancer MDT data 
collection and analysis, present illustrative examples and 
recommend future directions. 
Methods
A scoping review of the literature was performed. The 
protocol has not been previously published. English 
language publications in the National Library of Medicine 
database via the PubMed search engine with a focus on 
MDT-related clinical outcomes were searched for the 
previous decade, a time-period selected as likely high-yield 
for MDT publications relevant to up-to-date lung cancer 
management. The key words ‘MDT’ and ‘lung cancer’ 
and ‘data’ were used with no additional publications were 
identified using the search terms ‘multi-disciplinary team’, 
‘tumor board’, ‘audit’ or ‘analysis’. Papers were included if 
they had a primary focus on lung cancer multidisciplinary 
team care, referring MDT team meetings, or on MDT care 
across multiple tumour streams including lung cancer MDT 
meetings. Papers were excluded if they did not include lung 
cancer, MDT care and lung cancer outcomes. Reference 
lists of retrieved papers were hand-searched for additional 
relevant publications. MDT and study characteristics 
including country or origin, time period of data collection, 
tumour stream (if not dedicated lung cancer), number of 
subjects, impact of MDT on outcomes (if measured), data 
sources for MDT, nature of MDT dataset and presence or 
absence of digital data linkage were recorded for descriptive 
analysis.
Results
Publications with a focus on lung-cancer MDT-related 
clinical outcomes were identified. For the period 2009–
2019, the search strategy identified 25 studies, 19 were 
excluded as not relevant to the study aim and 7 studies were 
added from hand-searching reference lists (see Figure 1 
for search results). The studies are summarised in Table 1. 
Thirteen studies were identified from six countries. The 
number of subjects ranged from 47 (single institutional 
study) to 129,052 from the National Lung Cancer Audit in 
the UK. Most studies were retrospective cohort analyses 
with one single centre prospective analysis of MDT 
discussion. The impact of MDT discussion was measured 
in 11/13 studies and was positive in 8/11 studies. Datasets 
included patient and tumour details, investigations, referral 
patterns, treatment and hospital details and, for the one 
study that investigated cancer centres, measures of process 
and outcomes. Most (10/13) studies focussed on lung 
cancer with the remaining 3/10 investigating multiple 
tumour streams including lung cancer. Clinical outcomes 
included the impact of MDT presentation and care on 
treatment rates, survival, change in management plan pre-
and post-survival, adherence to treatment-related guidelines 
and other factors such as rates of emergency department 
presentation. The interval between the end of the data 
period studied and the year of publication measured 
approximately 53±32 months (average ± SD). 
Data sources differed between the studies with some 
overlap as shown in Table 1. Three studies used MDT 
records (13,25,26), three used medical records (13,26,27), five 
used institutional registries (7,10-12,27) and six used state or 
national administrative datasets or registries (8,9,27-30). Of 
the studies identified, 10/13 used data linkage, registry and/
or administrative data (7-12,27-30) with 3/13 basing their 
analyses on MDT or medical records (13,25,26). The three 
largest studies (with >10,000 cases) based their analyses on 
large, national registry and administrative datasets (9,28,30). 
Differences in outcomes related to MDT presentation were 
identified in the 10/13 studies that used data linkage and 
in 1/3 that did not (13). It is premature to ascertain any 
pattern between findings of positive impact of MDT and 
Figure 1 Results of literature search.
Initial PubMed search 
25 studies
19 studies rejected  
    •  2 not lung cancer  
    •  1 not cancer 
    •  10 not MDT 




13 studies for final 
analysis 
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Table 1 Studies included in the review for impact of MDT-related data on lung cancer clinical outcomes
Reference Country Data period Study design Tumour stream 
studied
N Impact of MDT Data sources Minimum dataset Digital data linkage 
Nadaraja 2019 
(25)
Denmark Jan 2016–Jun 
2018
Single centre open RCT; 
randomization to a geriatric screening 
tool
Multiple 151 Not measured MDT decision recorded by 
treating oncologist
Patient details; CGA* 





Germany Feb 2017–Jul 
2017
Prospective single-centre analysis 
of consecutive patients discussed at 
MDT
Multiple 47 Not measured MDT registration forms; nursing 
and medical records
Patient details; tumour 
details
None
Stone 2018 (11) Australia Jan 2006– 
Dec 2012
Retrospective single centre analysis 
of all lung cancer patients
Lung 1,197 Improved survival Institutional cancer registry Patient details; tumour 
details




USA 2002–2016 Retrospective single centre analysis 
of all lung cancer patients 
Lung 4,271 Improved survival Institutional cancer registry Patient details; tumour 
details; treatment details
MDT database linked to 
institutional cancer registry
Ung 2016 (13) Australia Mar–May 
2011
Retrospective single-centre analysis 
of consecutive lung cancer patients 
discussed at MDT
Lung 68 Change in treatment 
plan
MDT records; hospital records Patient details; tumour 
details; referral patterns
None 
Boxer 2016 (27) Australia Dec 2005–
Dec 2010
Retrospective single centre analysis 
of new lung cancer patients 
discussed at MDT
Lung 808 No change in 
adherence to 
treatment guidelines
Institutional cancer registry; State 
Births, Deaths and Marriages 
registry; electronic medical record





Data extracted from 
institutional cancer registry
Pan 2015 (9) Taiwan 2005–2010 Retrospective analysis of national 
cohort of new lung cancer patients 
Lung 32,569 Improved survival 
stages III and IV 
NSCLC
National Cancer Registry; 
National Health Insurance 
Research Database; National 
Cause of Death data 
Patient details; tumour 
details; hospital details 
Linkage of 3 national registries
Wang 2014 (28) Taiwan 2005–2007 Retrospective, longitudinal cohort 
study of lung cancer patients
Lung 22,817 Reduced emergency 
department visits
National Health Insurance 
Research Database
Patient details; hospital 
details; referral patterns




Australia Jan 2003–Jun 
2003
Retrospective analysis of all new 
diagnoses of lung cancer 
Lung 841 Better treatment 
receipt; improved 
survival
Victorian Cancer Registry Patient details; tumour 
details; treatment details 




USA 2001–2004 Survey of VA*** medical centres Multiple 138 
facilities
No change VA registry; VA administrative 
data; National Death Index; 
survey 
Measures of cancer care, 
processes and outcomes 
Linkage of 3 registries
Beckett 2012 
(30)
UK 2006–2010 Retrospective analysis of all NSCLC 
cases submitted to NLCA† (England)
Lung 129,052 No impact of volume 
of MDT case-load
NLCA (England only) MDT discussion** stratified 
by case-load; patient details; 
tumour details; treatment 
details 
Data extracted from national 
registry (audit)
Boxer 2011 (12) Australia Dec 2005–
Dec 2008
Retrospective single centre analysis 
of new lung cancer patients
Lung 988 Better treatment 
receipt
Institutional cancer registry Patient details; tumour 
details; treatment details 




Australia Jan 2006–Mar 
2008
Retrospective single centre analysis 
of all patients with histological 
NSCLC
Lung 98 Improved survival Institutional cancer registry Patient details; tumour 
details; treatment details 
Data extracted from 
institutional cancer registry
*, CGA, comprehensive geriatric assessment; **, a surrogate marker (place-first-seen) was used to indicate location (and event) of MDT discussion; ***, VA, Veterans Affairs; †, NLCA, National Lung Cancer Audit.
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data sources used (local vs. registry).
Closer review of several of these papers better illustrates 
how the MDT analyses were performed and the types 
of questions answerable from different data sources. We 
have selected three studies that demonstrated a positive 
impact and that used different data sources: a small single-
institution study that investigated details of MDT practice 
through analyses of local data, a large single-institution 
study that used institutional cancer registry data for MDT-
related survival analysis and a large, countrywide Taiwanese 
study that interrogated linked administrative datasets to 
evaluate MDT-related survival across a nationally-based 
cohort. 
Single-institutional study based on local data
The prospective cohort study by Ung et al. (13) derives 
information from consecutively enrolled cases presented 
to the institutional lung cancer MDT over an 11-week 
period. One investigator extracted clinical information and 
a proposed management plan from the electronic form 
routinely submitted to the MDT and contacted clinicians 
directly if data were missing. Cases were excluded if critical 
data (the pre-MDT management plan, critical clinical 
information such as staging) were not available. A second 
investigator, blinded to the pre-MDT plan, collected 
MDT recommendations. Subsequent hospital record 
review several months later was performed to check rates of 
implementation of the MDT recommendations. Sixty-eight 
cases were recruited, with 13 excluded due to missing data. 
Fifty-five cases were analysed. This study is characterized by 
detailed, personalized collection of data with individualized 
follow up of a small study sample for missing information 
and asks particular practice questions suitable for small-
scale study design that may not be answerable from larger 
datasets.
Larger, single institutional study based on local registry 
data
The longitudinal cohort study by Bilfinger et al. (10) is the 
largest of the single-institution studies that reviewed and 
obtained data from an institutional cancer registry over a 
15-year period. The study cross-linked the cancer registry 
with the local Lung Cancer Evaluation Centre MDT 
database, which allowed the investigators to identify 1,956 
lung MDT cases (defined by at least one clinical encounter 
with MDT clinicians and MDT presentation) and 2,315 
“non-MDT” cases. Data drawn from the registry included 
patient and tumour characteristics although not performance 
status, details of prior therapy or date of first detection. 
The two groups were compared using standard statistical 
methods, were stratified by date (of entry into the registry) 
to minimize confounding for improvements in survival 
over time and propensity-matched analyses were used to 
minimize selection bias. The risk of crossover between 
groups was addressed. This study used a retrospective 
registry cohort to analyse lung cancer outcomes and related 
them to MDT care, acknowledging missing clinical details 
and using standard, although imperfect (31) statistical 
methods to account for confounding factors. The primary 
aim was to compare survival between the two groups, a 
question that requires information and methods not likely 
including in local MDT data collections such as longer-
term outcomes and links to administrative datasets.
Large, national analysis based on linked national 
administrative datasets
The retrospective, nationwide cohort study by Pan et al. (9) 
analyses data newly diagnosed lung cancer cases recorded 
in the Taiwanese national cancer registry during a five-year 
period. The study combined data from three administrative 
datasets: the Taiwan Cancer Registry; the National Health 
Insurance Research Database; and, the Cause of Death 
Statistics Database, to extract information for 32,569 cases 
of non-small cell lung cancer (NSCLC) who had received 
treatment in the first year. The study analysed the cohort 
for participation in MDT and related this to a number of 
patent and health service characteristics using propensity 
score analysis to balance the MDT and non-MDT groups. 
Similar to the Bilfinger study above, this study aimed 
primarily to determine the impact of MDT care on survival 
for each stage of NSCLC and detected a benefit for stages 
III and IV but not for earlier stage disease although the 
distinction between the two groups was small. That a 
difference was found at all may possibly be due to the large 
size of the cohort and depend therefore on the health 
system infrastructure that collects, stores and links relevant 
information, including MDT participation, at a national 
scale. 
Discussion
In this review article, we have found diversity in lung 
cancer MDT reporting and in the sophistication of 
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data linkage across sources, with impediments such as 
time delays that compete with clinical needs for close 
to real-time review. In many settings, MDT meetings 
have developed as primarily clinical meetings with 
subsequent introduction of rules, expectations and 
standards. Current published guidelines from statutory 
bodies such as the NHS National  Cancer Action 
Team (32) and the American College of Surgeons (33) 
describe expected practices and refer generally, but not 
specifically to aspects of MDT or tumour board cancer 
data collection, audit and analysis. The more specific 
recommendations from the NHS NCAT and include 
reference to resources, high impact data, national mandated 
data sets data feedback to teams, audit and review activities 
and patient input, although do not prescribe detailed MDT 
datasets. The NCAT recommendations for data collection, 
analysis and audit of outcomes cover the following points:
(I) Data collection resources are available to the MDT;
(II) Key information that directly affects treatment 
decisions (such as stage, performance status etc) is 
collected by the MDT;
(III) Mandated national datasets are populated before or 
during MDT meetings;
(IV) Data collected during MDT meetings is analysed 
and subject to feedback;
(V) The MDT participates in audits of processes and 
outcomes and changes practice where necessary;
(VI) MDTs incorporate clinical outcomes data made 
available through (e.g.) peer review and clinical 
reference groups;
(VII) Patients experience surveys include questions on 
MDTs and MDTs respond to patient feedback.
Our group has published an optimal minimum dataset 
for lung cancer MDTs (34) developed through a modified 
Delphi consensus method and the International Consortium 
for Health Outcomes Measurement has defined a larger 
dataset based on patient-centred outcomes (35). To our 
knowledge, no other recommended datasets have been 
published. A UK study that surveyed over 1,200 MDT 
members for views on streamlining discussion (36) infers 
the need for MDT data although does not specify data 
items for collection. In this study, survey responses favoured 
auditing patients placed on protocolized management 
pathways, raised concerns about the effect of streamlining 
on quality and safety of care and supported collecting 
evidence on the impact of MDT innovations on clinical 
outcomes to overcome limitations of existing evidence. One 
of the most comprehensive data environments for MDTs is 
based in the Australian state of Queensland where Cancer 
Alliance Queensland (37) hosts QOOL (38), a platform 
that integrates data from various sources with an emphasis 
on the provision of “just-in-time” clinical information (39) 
to clinicians and MDTs for clinical care and research. 
Integration of MDT data through the QOOL platform 
with a focus on rapid access to timely information has the 
potential for “real-time” impact on clinical decisions. At 
the time of writing, QOOL is used by 67 MDTs across 
Queensland (38) and is in development for the state of 
Victoria (40).
The impact of MDT care on lung cancer outcomes 
appears promising. Studies included in this review suggested 
improvements across clinical outcomes including survival, 
treatment receipt and changes in treatment plans post-
MDT presentation. In this issue, Heinke and Vinod (41) 
present a more extensive evaluation of the effects of 
MDT care on clinical lung cancer outcomes including 
survival, treatment details, referral patterns and patient-
reported outcomes. Information transfer from MDTs 
to large collections can support cancer registries even 
at national level such as the UK NLCA, which can then 
report on outcomes and quality of care as in its most recent 
2018 report (41,42). The institution of the NLCA and 
regular reporting, supported by these data, have seen an 
improvement in outcomes for lung cancer including most 
recently, an increase in tissue confirmation in early stage 
disease, in systemic therapy for both NSCLC and small 
cell lung cancer (SCLC) and in surgical rates (42). MDT 
data have the potential to support research, as is shown by 
the series of papers reviewed in this manuscript, as well as 
team-based quality assurance activities. However, many 
questions persist about the best way to implement more 
comprehensive MDT data collection including the specifics 
of datasets, resources required, strategies for feedback and 
how to link datasets effectively.
The datasets analysed for these studies all differ, 
ranging from local clinical registries to large administrative 
datasets. In some settings data collected by MDTs may 
contribute to larger datasets and subsequent analyses. In 
many cases, clinicians do not have ready access to these 
larger, population-based datasets, which themselves are 
not designed to provide immediate, real-time insights 
into patient outcomes. The benefits of “knowing your 
own data”, include quality assurance and improvement 
activities, benchmarking against guidelines and peers and 
other centres and development of research questions. The 
proliferation of MDT-related research papers over recent 
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years indicates a strong interest in MDT practice. Research 
from our group has identified positive responses from MDT 
clinicians to modelled data feedback, representing their own 
clinical cohorts (43).
The effects of real-time clinical data feedback on practice 
and outcomes in lung cancer MDT care remain enticing, 
but as yet not established. The workings and impact of 
QOOL have not yet been published. National lung cancer 
audits such as in the UK above, Denmark (44) and the 
Netherlands (16,45) demonstrate the effects of systems 
that include institutional data feeds into national registries, 
portals for feedback and subsequent benchmarking. Smaller 
scale studies have tested details of audit and feedback to 
clinicians both in lung cancer(43,46) and other fields (47) 
but there is little if any (to our knowledge) literature on the 
effects of real-time, clinical data feedback to lung cancer 
MDTs on clinical outcomes. Cancer outcomes data are 
often delayed, even in this series of papers with an average 
of over four years between the data collection period and 
publication of the paper. Epidemiological datasets take time 
to clean, privacy laws delay access and need for accuracy 
and completeness delays reporting. The use of links to 
administrative datasets for clinical practice and research 
carries appeal (large amounts of data, population-based 
relevance) but also has limitations, best summarised in a 
review of linked data in nephrology in Australia but with 
broadly applicable concepts—limitations of content for 
routinely collected data (timing, quality, completeness, 
missing data such as treatment details) and delays and access 
barriers imposed by “concerns about data ownership privacy 
and confidentiality” (23).
The combination of digitized health care data and 
increasingly accessible systems such as QOOL can give 
clinicians unprecedented access to vast pools of data. 
However, much of this information risks sitting unused 
for clinical practice improvements (as opposed to use for 
health services research, for example) unless it is relevant, 
timely and informative for clinical purposes. MDT data 
collection is not yet ideal. We do not have a clear record of 
what information is currently collected by most MDTs, or 
how it is stored and analysed. We do not have established 
standard datasets for MDTs, although several have been 
published. There may be room for MDT data integration 
into national lung cancer clinical registries. Limited data 
suggest that MDT care has a positive impact on lung cancer 
outcomes and access to registry data may allow analysis of 
larger cohorts across longer time frames. The benefits of 
routinely collected, standardized MDT data collections 
warrant exploration and may include better benchmarking, 
evaluation of key indicators and improvements in outcomes. 
The benefits of data linkage (which may also impair 
currency of data) may include larger study cohorts, more 
rapid access to data such as survival and better evaluation 
of quality of care. For MDT clinicians, the goal persists—
rapid, easy access to timely and comprehensive information 
that leads to practice change and better outcomes for 
patients.
Conclusions and recommendations
Multidisciplinary team care in lung cancer is broadly 
supported by international clinical groups and statutory 
bodies and may improve patient outcomes. Integration of 
prompt information feedback into routine MDT operation 
has not been widely studied and the collection of clinical 
data by lung cancer MDTs has not yet been well-defined or 
implemented. Standardized datasets, integrated real-time 
platforms and appropriate data linkage all have potential to 
optimize the quality and relevance of MDT data collections, 
which may lead to improvements in benchmarking, quality 
activities and even patient outcomes. 
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